$NK The news today that Remdesivir may not benefit patients with severe cases may be the windfall Patrick was after. Hopefully, by late June there is news that the BM-Allo.MSC does alleviate patients in ICU/respirators. In my view, if successful, this will bring big bucks and a big boy to back further testing/production. And as a derivative, help validate NK's cancer research/trials. Any good news associated to the vaccine will be a 3rd derivative. It will enhance PSS's reputation to such a point investors will seek to invest on any of his public companies. NK being the one with most visibility.